A REFRACTORY CASE OF PYODERMA GANGRENOSUM RESPONDING TO INFLIXIMAB
DC Field | Value | Language |
---|---|---|
dc.contributor.author | So, Byoung Joon | - |
dc.contributor.author | Chun, Seung Hyun | - |
dc.contributor.author | Lee, Ji Min | - |
dc.contributor.author | Jung, Sung Kyu | - |
dc.contributor.author | Kim, Il-Hwan | - |
dc.date.accessioned | 2021-09-05T04:53:50Z | - |
dc.date.available | 2021-09-05T04:53:50Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-10 | - |
dc.identifier.issn | 0385-2407 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/97328 | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.title | A REFRACTORY CASE OF PYODERMA GANGRENOSUM RESPONDING TO INFLIXIMAB | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Il-Hwan | - |
dc.identifier.wosid | 000344332600616 | - |
dc.identifier.bibliographicCitation | JOURNAL OF DERMATOLOGY, v.41, pp.104 - 104 | - |
dc.relation.isPartOf | JOURNAL OF DERMATOLOGY | - |
dc.citation.title | JOURNAL OF DERMATOLOGY | - |
dc.citation.volume | 41 | - |
dc.citation.startPage | 104 | - |
dc.citation.endPage | 104 | - |
dc.type.rims | ART | - |
dc.type.docType | Meeting Abstract | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Dermatology | - |
dc.relation.journalWebOfScienceCategory | Dermatology | - |
dc.subject.keywordAuthor | pyoderma | - |
dc.subject.keywordAuthor | gangrenosum | - |
dc.subject.keywordAuthor | infliximab | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.